IktosIktos
Iktos

Iktos

AI-powered drug discovery platform for accelerated molecular design.

2017Active

About

Iktos pioneers AI and robotics for drug discovery, offering an integrated platform that transforms the development of new treatments. Their core offerings include Makya, a generative AI platform for molecular design, and Spaya, an AI-driven retrosynthesis tool, both designed to accelerate the DMTA cycle. Iktos serves chemists and researchers by providing solutions for innovative molecular design, efficient synthesis planning, and fully automated laboratory processes.

Technology stack

detected 2026-06-17
Est. monthly stack spend~$200/mo
CDN
Vercel
Emailunknown
Hosting
Vercel
Stack
Next.js
Analytics
Google Tag Manager
Video
YouTube
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Iktos do?

Iktos pioneers AI and robotics for drug discovery, offering an integrated platform that transforms the development of new treatments. Their core offerings include Makya, a generative AI platform for molecular design, and Spaya, an AI-driven retrosynthesis tool, both designed to accelerate the DMTA cycle. Iktos serves chemists and researchers by providing solutions for innovative molecular design, efficient synthesis planning, and fully automated laboratory processes.

How much funding has Iktos raised?

Iktos has raised a total of $2M in funding. The most recent round on record is Seed.

Where is Iktos headquartered?

Iktos is headquartered in Paris, France.

When was Iktos founded?

Iktos was founded in 2017.

What industry does Iktos operate in?

Iktos operates in AI Drug Discovery, Biotech, HealthTech, Drug Discovery, Generative AI, Foundation Model.